CA2558718C - Anti-human tenascin monoclonal antibody - Google Patents
Anti-human tenascin monoclonal antibody Download PDFInfo
- Publication number
- CA2558718C CA2558718C CA2558718A CA2558718A CA2558718C CA 2558718 C CA2558718 C CA 2558718C CA 2558718 A CA2558718 A CA 2558718A CA 2558718 A CA2558718 A CA 2558718A CA 2558718 C CA2558718 C CA 2558718C
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- derivatives
- tenascin
- vial
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000007000 Tenascin Human genes 0.000 title claims abstract description 58
- 108010008125 Tenascin Proteins 0.000 title claims abstract description 58
- 239000012634 fragment Substances 0.000 claims abstract description 55
- 101000666340 Homo sapiens Tenascin Proteins 0.000 claims abstract description 25
- 230000002797 proteolythic effect Effects 0.000 claims abstract description 19
- 230000000890 antigenic effect Effects 0.000 claims abstract description 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 88
- 108090001008 Avidin Proteins 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 22
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 21
- 241001529936 Murinae Species 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 229960002685 biotin Drugs 0.000 claims description 15
- 239000011616 biotin Substances 0.000 claims description 15
- 235000020958 biotin Nutrition 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 13
- 210000004408 hybridoma Anatomy 0.000 claims description 11
- 238000011363 radioimmunotherapy Methods 0.000 claims description 11
- 108020004414 DNA Proteins 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 206010018338 Glioma Diseases 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- 108010090804 Streptavidin Proteins 0.000 claims description 7
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 230000009885 systemic effect Effects 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000012636 effector Substances 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 230000001900 immune effect Effects 0.000 claims description 5
- 150000002678 macrocyclic compounds Chemical class 0.000 claims description 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 229940127557 pharmaceutical product Drugs 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 238000012286 ELISA Assay Methods 0.000 claims description 4
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 231100000617 superantigen Toxicity 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- -1 -OH Chemical group 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 102100032401 Charged multivesicular body protein 2a Human genes 0.000 description 43
- 101000943253 Homo sapiens Charged multivesicular body protein 2a Proteins 0.000 description 43
- 201000011510 cancer Diseases 0.000 description 26
- 230000008685 targeting Effects 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 150000001615 biotins Chemical class 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000009738 saturating Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 102000057345 human TNC Human genes 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 241000589565 Flavobacterium Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
- 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000022811 deglycosylation Effects 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 238000013411 master cell bank Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 241000228193 Aspergillus clavatus Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930182474 N-glycoside Natural products 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 229940051173 recombinant immunotoxin Drugs 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000105A ITRM20040105A1 (it) | 2004-02-27 | 2004-02-27 | Anticorpo monoclonale antitenascina umana. |
| ITRM2004A000105 | 2004-02-27 | ||
| PCT/IT2005/000078 WO2005082938A2 (en) | 2004-02-27 | 2005-02-16 | Anti-human tenascin monoclonal antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2558718A1 CA2558718A1 (en) | 2005-09-09 |
| CA2558718C true CA2558718C (en) | 2015-01-13 |
Family
ID=34897820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2558718A Expired - Fee Related CA2558718C (en) | 2004-02-27 | 2005-02-16 | Anti-human tenascin monoclonal antibody |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7989171B2 (enExample) |
| EP (1) | EP1718678B1 (enExample) |
| JP (1) | JP5191036B2 (enExample) |
| KR (1) | KR101266389B1 (enExample) |
| CN (1) | CN1946740B (enExample) |
| AR (1) | AR047819A1 (enExample) |
| AU (1) | AU2005217237B2 (enExample) |
| BR (1) | BRPI0508082A8 (enExample) |
| CA (1) | CA2558718C (enExample) |
| ES (1) | ES2654065T3 (enExample) |
| IT (1) | ITRM20040105A1 (enExample) |
| MX (1) | MXPA06009674A (enExample) |
| PL (1) | PL1718678T3 (enExample) |
| PT (1) | PT1718678T (enExample) |
| WO (1) | WO2005082938A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006086769A2 (en) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| JP2012031084A (ja) * | 2010-07-29 | 2012-02-16 | Tokyo Univ Of Science | 抗腫瘍剤 |
| WO2014113459A1 (en) * | 2013-01-15 | 2014-07-24 | Duke University | Hiv-1 neutralizing factor |
| EP2999967B1 (en) | 2013-05-21 | 2020-05-20 | NX Pharmagen | Use of tenascin-c as an extracellular marker of tumor-derived microparticles |
| GB201414021D0 (en) * | 2014-08-07 | 2014-09-24 | Nascient Ltd | Biological materials and uses thereof |
| GB201616596D0 (en) * | 2016-09-29 | 2016-11-16 | Nascient Limited | Epitope and antibodies |
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals Inc | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
| CN119019548B (zh) * | 2022-07-05 | 2025-06-24 | 东莞市朋志生物科技有限公司 | 抗甲型流感病毒抗体、检测甲型流感病毒的试剂和试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5634076A (en) * | 1994-10-04 | 1997-05-27 | Analog Devices, Inc. | DMA controller responsive to transition of a request signal between first state and second state and maintaining of second state for controlling data transfer |
| US6014709A (en) * | 1997-11-05 | 2000-01-11 | Unisys Corporation | Message flow protocol for avoiding deadlocks |
| US6335014B1 (en) * | 1998-06-17 | 2002-01-01 | The Institute Of Physical And Chemical Research | Medicament for suppressing cancer metastasis |
| US6521593B1 (en) * | 1999-02-01 | 2003-02-18 | Childrens Hospital Los Angeles | Methods for inhibiting brain tumor growth |
| AU4682100A (en) * | 1999-05-01 | 2000-11-17 | University Of Medicine And Dentistry Of New Jersey | Neurite outgrowth and guidance by tenascin-c |
| US7058750B1 (en) * | 2000-05-10 | 2006-06-06 | Intel Corporation | Scalable distributed memory and I/O multiprocessor system |
| JP3646159B2 (ja) * | 2001-02-08 | 2005-05-11 | 国立大学法人三重大学 | 抗テネイシンｃモノクローナル抗体及び当該抗体を産生するハイブリドーマ |
| ITRM20010079A1 (it) * | 2001-02-16 | 2002-08-16 | Sigma Tau Ind Farmaceuti | Amminoderivati della biotina e loro coniugati con chelanti macrociclici. |
| SI1478667T1 (sl) * | 2002-02-26 | 2010-12-31 | Sigma Tau Ind Farmaceuti | Monoklonski protitelesni anti-äśloveĺ ki tenascin |
| ITRM20020128A1 (it) * | 2002-03-08 | 2003-09-08 | Sigma Tau Ind Farmaceuti | Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting". |
-
2004
- 2004-02-27 IT IT000105A patent/ITRM20040105A1/it unknown
-
2005
- 2005-02-16 MX MXPA06009674A patent/MXPA06009674A/es active IP Right Grant
- 2005-02-16 PT PT57189888T patent/PT1718678T/pt unknown
- 2005-02-16 BR BRPI0508082A patent/BRPI0508082A8/pt not_active IP Right Cessation
- 2005-02-16 CN CN2005800061324A patent/CN1946740B/zh not_active Expired - Fee Related
- 2005-02-16 US US10/590,936 patent/US7989171B2/en not_active Expired - Fee Related
- 2005-02-16 AU AU2005217237A patent/AU2005217237B2/en not_active Ceased
- 2005-02-16 EP EP05718988.8A patent/EP1718678B1/en not_active Expired - Lifetime
- 2005-02-16 CA CA2558718A patent/CA2558718C/en not_active Expired - Fee Related
- 2005-02-16 PL PL05718988T patent/PL1718678T3/pl unknown
- 2005-02-16 WO PCT/IT2005/000078 patent/WO2005082938A2/en not_active Ceased
- 2005-02-16 JP JP2007500356A patent/JP5191036B2/ja not_active Expired - Fee Related
- 2005-02-16 ES ES05718988.8T patent/ES2654065T3/es not_active Expired - Lifetime
- 2005-02-24 AR ARP050100671A patent/AR047819A1/es not_active Application Discontinuation
-
2006
- 2006-09-27 KR KR1020067020062A patent/KR101266389B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005082938A2 (en) | 2005-09-09 |
| HK1100848A1 (en) | 2007-09-28 |
| EP1718678B1 (en) | 2017-10-11 |
| WO2005082938A3 (en) | 2005-12-15 |
| AU2005217237A1 (en) | 2005-09-09 |
| KR101266389B1 (ko) | 2013-05-28 |
| ES2654065T3 (es) | 2018-02-12 |
| ITRM20040105A1 (it) | 2004-05-27 |
| AU2005217237B2 (en) | 2011-12-22 |
| JP5191036B2 (ja) | 2013-04-24 |
| BRPI0508082A (pt) | 2007-07-17 |
| PL1718678T3 (pl) | 2018-05-30 |
| CN1946740A (zh) | 2007-04-11 |
| CA2558718A1 (en) | 2005-09-09 |
| KR20070002029A (ko) | 2007-01-04 |
| US7989171B2 (en) | 2011-08-02 |
| JP2008506355A (ja) | 2008-03-06 |
| MXPA06009674A (es) | 2007-03-21 |
| BRPI0508082A8 (pt) | 2017-12-26 |
| PT1718678T (pt) | 2017-12-29 |
| US20100297003A1 (en) | 2010-11-25 |
| CN1946740B (zh) | 2012-09-05 |
| AR047819A1 (es) | 2006-02-22 |
| EP1718678A2 (en) | 2006-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8048417B2 (en) | Anti-human tenascin monoclonal antibody | |
| US7090844B2 (en) | Use of antibodies against the MUC18 antigen | |
| US7067131B2 (en) | Methods for using anti-MUC18 antibodies | |
| US7378091B2 (en) | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen | |
| US20240269307A1 (en) | Anti-nectin-4 antibody and anti-nectin-4 antibody-drug conjugate, and medicinal use thereof | |
| JP2023510905A (ja) | 抗ｔｒｏｐ－２抗体－エキサテカン類似体複合体及びその医薬用途 | |
| JP2023505708A (ja) | 抗クローディン抗体薬物複合体及びその医薬用途 | |
| JP2022514786A (ja) | Ｍｕｃ１８に特異的な抗体 | |
| CA2558718C (en) | Anti-human tenascin monoclonal antibody | |
| JP2023506805A (ja) | 抗ｃｅａ抗体－エキサテカン類似体複合体及びその医薬用途 | |
| EP4458850A1 (en) | Anti-ror1 antibody, and anti-ror1 antibody-drug conjugate and medical uses thereof | |
| CN116574187B (zh) | 针对gucy2c的抗体及其用途 | |
| CN118324916B (zh) | 一种抗人gprc5d的单克隆抗体及其制备方法和用途 | |
| RU2833323C1 (ru) | Конъюгат антитела против cea и аналога эксатекана и его фармацевтическое применение | |
| HK1100848B (en) | Anti-human tenascin monoclonal antibody | |
| WO2025031285A1 (zh) | 抗psma抗体-药物偶联物及其医药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210831 |
|
| MKLA | Lapsed |
Effective date: 20200217 |